Reporters for the "Alternative" NF-kB Pathway

This assay can identify potential drug candidates to treat B-cell-dependent autoimmune diseases, such as lupus and lymphomas. It is ideally suited for high-throughput screening, thereby making it an essential tool for drug discovery and research.

A second major NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cell) pathway has been described. This protein complex controls the transcription of DNA and is important for the maturation of B cells and the development of secondary lymphoid organs. In order to identify agents that specifically affect this pathway, and not the classical NF-kB cascade, UC San Diego researchers have developed a method to assay for inhibitors specific to this biochemical pathway and no other. Specifically, this technology is a method for identifying compounds that alters binding of the RelB Rel homology domain (RelB RHD) with the RelB sequence.

Patent Number: US8227193B2
Application Number: US2003574333A
Inventor: Karin, Michael | Bonizzi, Giussepina | Bebien, Magali
Priority Date: 1 Oct 2003
Priority Number: US8227193B2
Application Date: 21 Jul 2008
Publication Date: 24 Jul 2012
IPC Current: C12Q000168 | C07H002104 | C07K001447 | G01N003368
US Class: 43500619 | 5360241
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for gene expression
Usefulness: Compositions and methods for gene expression
Summary: For identifying therapeutic compound that alters binding of RelB Rel homology domain (RelB RHD) with RelB-kappaB sequences (claimed); and the therapeutic compounds that alter inhibitor of nuclear factor kappa-B kinase alpha (IKK-α) subunit related pathologies.
Novelty: Isolated nucleotide sequences mediating functions of inhibitor of nuclear factor kappa-B kinase alpha subunit useful for identifying therapeutic compounds that alter the subunit related pathologies

生物醫學

DNA /基因工程

8227193

Related Materials

• U.S. Patent Application (Pub. No. US-2008-0280286) Compositions and Methods for Gene Expression. Publication Date: 13Nov2008.
• PCT Patent Application (PCT/US2004/032246) Compositions and Methods for Gene Expression. Publication Date: 14Apr2005.
• Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, Jegga AG, Aronow BJ, Ghosh G, Rickert RC, Karin M. (2004) Activation of IKKalpha Target Genes Depends on Recognition of Specific kappaB Binding Sites by RelB:p52 Dimers. EMBO J. 2004 Oct 27;23(21):4202-10.
• Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF, Anzelon-Mills A, Rickert RC, Karin M. (2006) Alternative and Classical NF-Kappa B Signaling Retain Autoreactive B Cells in the Splenic Marginal Zone and Result in Lupus-Like Disease. Immunity 25(3):403-15.
• Vallabhapurapu S, Karin M (2009) Regulation and Function of NF-KappaB Transcription Factors in the Immune System. Annu Rev Immunol 27:693-733.

Tech ID/UC Case

19767/2003-196-0

Related Cases

2003-196-0

美國

桌面版